1
|
Cornejo PJ, Vergoni B, Ohanna M, Angot B, Gonzalez T, Jager J, Tanti JF, Cormont M. The Stress-Responsive microRNA-34a Alters Insulin Signaling and Actions in Adipocytes through Induction of the Tyrosine Phosphatase PTP1B. Cells 2022; 11:cells11162581. [PMID: 36010657 PMCID: PMC9406349 DOI: 10.3390/cells11162581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 08/02/2022] [Accepted: 08/05/2022] [Indexed: 11/18/2022] Open
Abstract
Metabolic stresses alter the signaling and actions of insulin in adipocytes during obesity, but the molecular links remain incompletely understood. Members of the microRNA-34 (miR-34 family play a pivotal role in stress response, and previous studies showed an upregulation of miR-34a in adipose tissue during obesity. Here, we identified miR-34a as a new mediator of adipocyte insulin resistance. We confirmed the upregulation of miR-34a in adipose tissues of obese mice, which was observed in the adipocyte fraction exclusively. Overexpression of miR-34a in 3T3-L1 adipocytes or in fat pads of lean mice markedly reduced Akt activation by insulin and the insulin-induced glucose transport. This was accompanied by a decreased expression of VAMP2, a target of miR-34a, and an increased expression of the tyrosine phosphatase PTP1B. Importantly, PTP1B silencing prevented the inhibitory effect of miR-34a on insulin signaling. Mechanistically, miR-34a decreased the NAD+ level through inhibition of Naprt and Nampt, resulting in an inhibition of Sirtuin-1, which promoted an upregulation of PTP1B. Furthermore, the mRNA expression of Nampt and Naprt was decreased in adipose tissue of obese mice. Collectively, our results identify miR-34a as a new inhibitor of insulin signaling in adipocytes, providing a potential pathway to target to fight insulin resistance.
Collapse
Affiliation(s)
- Pierre-Jean Cornejo
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
| | - Bastien Vergoni
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
| | - Mickaël Ohanna
- Université Côte d’Azur, Inserm, C3M, “Team Microenvironnement, Signalisation et Cancer”, 06204 Nice, France
| | - Brice Angot
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
| | - Teresa Gonzalez
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
- Aix Marseille Université, Inserm, INRAE, C2VN, 13385 Marseille, France
| | - Jennifer Jager
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
| | - Jean-François Tanti
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
| | - Mireille Cormont
- Université Côte d’Azur, Inserm, C3M, Team “Molecular and Cellular Physiopathology of Obesity and Diabetes”, 06204 Nice, France
- Correspondence: ; Tel.: +33-4-89-15-38-31
| |
Collapse
|
2
|
A xanthene derivative, DS20060511, attenuates glucose intolerance by inducing skeletal muscle-specific GLUT4 translocation in mice. Commun Biol 2021; 4:994. [PMID: 34417555 PMCID: PMC8379256 DOI: 10.1038/s42003-021-02491-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2020] [Accepted: 07/21/2021] [Indexed: 12/30/2022] Open
Abstract
Reduced glucose uptake into the skeletal muscle is an important pathophysiological abnormality in type 2 diabetes, and is caused by impaired translocation of glucose transporter 4 (GLUT4) to the skeletal muscle cell surface. Here, we show a xanthene derivative, DS20060511, induces GLUT4 translocation to the skeletal muscle cell surface, thereby stimulating glucose uptake into the tissue. DS20060511 induced GLUT4 translocation and stimulated glucose uptake into differentiated L6-myotubes and into the skeletal muscles in mice. These effects were completely abolished in GLUT4 knockout mice. Induction of GLUT4 translocation by DS20060511 was independent of the insulin signaling pathways including IRS1-Akt-AS160 phosphorylation and IRS1-Rac1-actin polymerization, eNOS pathway, and AMPK pathway. Acute and chronic DS20060511 treatment attenuated the glucose intolerance in obese diabetic mice. Taken together, DS20060511 acts as a skeletal muscle-specific GLUT4 translocation enhancer to facilitate glucose uptake. Further studies of DS20060511 may pave the way for the development of novel antidiabetic medicines.
Collapse
|
3
|
Abstract
The skeletal muscle is the largest organ in the body, by mass. It is also the regulator of glucose homeostasis, responsible for 80% of postprandial glucose uptake from the circulation. Skeletal muscle is essential for metabolism, both for its role in glucose uptake and its importance in exercise and metabolic disease. In this article, we give an overview of the importance of skeletal muscle in metabolism, describing its role in glucose uptake and the diseases that are associated with skeletal muscle metabolic dysregulation. We focus on the role of skeletal muscle in peripheral insulin resistance and the potential for skeletal muscle-targeted therapeutics to combat insulin resistance and diabetes, as well as other metabolic diseases like aging and obesity. In particular, we outline the possibilities and pitfalls of the quest for exercise mimetics, which are intended to target the molecular mechanisms underlying the beneficial effects of exercise on metabolic disease. We also provide a description of the molecular mechanisms that regulate skeletal muscle glucose uptake, including a focus on the SNARE proteins, which are essential regulators of glucose transport into the skeletal muscle. © 2020 American Physiological Society. Compr Physiol 10:785-809, 2020.
Collapse
Affiliation(s)
- Karla E. Merz
- Department of Molecular and Cellular Endocrinology, City of Hope Beckman Research Institute, Duarte, California, USA
- The Irell and Manella Graduate School of Biological Sciences, City of Hope, Duarte, California, USA
| | - Debbie C. Thurmond
- Department of Molecular and Cellular Endocrinology, City of Hope Beckman Research Institute, Duarte, California, USA
| |
Collapse
|
4
|
Wang B, Liu T, Wu Z, Zhang L, Sun J, Wang X. Synthesis and biological evaluation of stilbene derivatives coupled to NO donors as potential antidiabetic agents. J Enzyme Inhib Med Chem 2018; 33:416-423. [PMID: 29374975 PMCID: PMC7011920 DOI: 10.1080/14756366.2018.1425686] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
The work is focused on the design of drugs that prevent and treat diabetes and its complications. A novel class of stilbene derivatives were prepared by coupling NO donors of alkyl nitrate and were fully characterised by NMR and other techniques. These compounds were tested in vitro activity, including α-glucosidase inhibitory activity, aldose reductase (AR) inhibitory activity and advanced glycation end products (AGEs) formation inhibitory activity. A class of modified compounds could play a significant effect for treatment of diabetic complications. Target compounds 3e and 7c offered a potential drug design concept for the development of therapeutic or preventive agents for diabetes and its complications.
Collapse
Affiliation(s)
- Bing Wang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Teng Liu
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Zhongyu Wu
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Lei Zhang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Jie Sun
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| | - Xiaojing Wang
- a School of Medicine and Life Sciences , University of Jinan-Shandong Academy of Medical Sciences , Jinan , China.,b Institute of Materia Medica, Shandong Academy of Medical Sciences , Jinan , China.,c Key Laboratory for Biotech-Drugs Ministry of Health , Jinan , China.,d Key Laboratory for Rare & Uncommon Diseases of Shandong Province , Jinan , China
| |
Collapse
|
5
|
Zhang X, Hiam D, Hong YH, Zulli A, Hayes A, Rattigan S, McConell GK. Nitric oxide is required for the insulin sensitizing effects of contraction in mouse skeletal muscle. J Physiol 2017; 595:7427-7439. [PMID: 29071734 DOI: 10.1113/jp275133] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 10/18/2017] [Indexed: 01/15/2023] Open
Abstract
KEY POINTS People with insulin resistance or type 2 diabetes can substantially increase their skeletal muscle glucose uptake during exercise and insulin sensitivity after exercise. Skeletal muscle nitric oxide (NO) is important for glucose uptake during exercise, although how prior exercise increases insulin sensitivity is unclear. In the present study, we examined whether NO is necessary for normal increases in skeletal muscle insulin sensitivity after contraction ex vivo in mouse muscle. The present study uncovers, for the first time, a novel role for NO in the insulin sensitizing effects of ex vivo contraction, which is independent of blood flow. ABSTRACT The factors regulating the increase in skeletal muscle insulin sensitivity after exercise are unclear. We examined whether nitric oxide (NO) is required for the increase in insulin sensitivity after ex vivo contractions. Isolated C57BL/6J mouse EDL muscles were contracted for 10 min or remained at rest (basal) with or without the NO synthase (NOS) inhibition (NG -monomethyl-l-arginine; l-NMMA; 100 μm). Then, 3.5 h post contraction/basal, muscles were exposed to saline or insulin (120 μU ml-1 ) with or without l-NMMA during the last 30 min. l-NMMA had no effect on basal skeletal muscle glucose uptake. The increase in muscle glucose uptake with insulin (57%) was significantly (P < 0.05) greater after prior contraction (140% increase). NOS inhibition during the contractions had no effect on this insulin-sensitizing effect of contraction, whereas NOS inhibition during insulin prevented the increase in skeletal muscle insulin sensitivity post-contraction. Soluble guanylate cyclase inhibition, protein kinase G (PKG) inhibition or cyclic nucleotide phosphodiesterase inhibition each had no effect on the insulin-sensitizing effect of prior contraction. In conclusion, NO is required for increases in insulin sensitivity several hours after contraction of mouse skeletal muscle via a cGMP/PKG independent pathway.
Collapse
Affiliation(s)
- Xinmei Zhang
- Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, VIC, Australia.,School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia
| | - Danielle Hiam
- Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, VIC, Australia
| | - Yet-Hoi Hong
- Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, VIC, Australia
| | - Anthony Zulli
- College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia
| | - Alan Hayes
- Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, VIC, Australia.,College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia
| | - Stephen Rattigan
- Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
| | - Glenn K McConell
- Institute of Sport, Exercise and Active Living (ISEAL), College of Sport and Exercise Science, Victoria University, Melbourne, VIC, Australia.,College of Health and Biomedicine, Victoria University, Melbourne, VIC, Australia
| |
Collapse
|
6
|
Vergoni B, Cornejo PJ, Gilleron J, Djedaini M, Ceppo F, Jacquel A, Bouget G, Ginet C, Gonzalez T, Maillet J, Dhennin V, Verbanck M, Auberger P, Froguel P, Tanti JF, Cormont M. DNA Damage and the Activation of the p53 Pathway Mediate Alterations in Metabolic and Secretory Functions of Adipocytes. Diabetes 2016; 65:3062-74. [PMID: 27388216 DOI: 10.2337/db16-0014] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2016] [Accepted: 07/01/2016] [Indexed: 11/13/2022]
Abstract
Activation of the p53 pathway in adipose tissue contributes to insulin resistance associated with obesity. However, the mechanisms of p53 activation and the effect on adipocyte functions are still elusive. Here we found a higher level of DNA oxidation and a reduction in telomere length in adipose tissue of mice fed a high-fat diet and an increase in DNA damage and activation of the p53 pathway in adipocytes. Interestingly, hallmarks of chronic DNA damage are visible at the onset of obesity. Furthermore, injection of lean mice with doxorubicin, a DNA damage-inducing drug, increased the expression of chemokines in adipose tissue and promoted its infiltration by proinflammatory macrophages and neutrophils together with adipocyte insulin resistance. In vitro, DNA damage in adipocytes increased the expression of chemokines and triggered the production of chemotactic factors for macrophages and neutrophils. Insulin signaling and effect on glucose uptake and Glut4 translocation were decreased, and lipolysis was increased. These events were prevented by p53 inhibition, whereas its activation by nutlin-3 reproduced the DNA damage-induced adverse effects. This study reveals that DNA damage in obese adipocytes could trigger p53-dependent signals involved in alteration of adipocyte metabolism and secretory function leading to adipose tissue inflammation, adipocyte dysfunction, and insulin resistance.
Collapse
Affiliation(s)
- Bastien Vergoni
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Pierre-Jean Cornejo
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Jérôme Gilleron
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Mansour Djedaini
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Franck Ceppo
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Arnaud Jacquel
- Université Côte d'Azur, C3M, Nice, France INSERM, UMR 1065, C3M, Team 2 Cell Death, Differentiation and Cancer, Nice, France
| | - Gwennaelle Bouget
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Clémence Ginet
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Teresa Gonzalez
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France INSERM, UMR 1062, Nutrition, Obesity and Risk of Thrombosis, Marseille, France
| | - Julie Maillet
- CNRS, UMR 8199, Lille Pasteur Institute, Lille, France Lille University, Lille, France European Genomic Institute for Diabetes, Lille, France
| | - Véronique Dhennin
- CNRS, UMR 8199, Lille Pasteur Institute, Lille, France Lille University, Lille, France European Genomic Institute for Diabetes, Lille, France
| | - Marie Verbanck
- CNRS, UMR 8199, Lille Pasteur Institute, Lille, France Lille University, Lille, France European Genomic Institute for Diabetes, Lille, France
| | - Patrick Auberger
- Université Côte d'Azur, C3M, Nice, France INSERM, UMR 1065, C3M, Team 2 Cell Death, Differentiation and Cancer, Nice, France
| | - Philippe Froguel
- CNRS, UMR 8199, Lille Pasteur Institute, Lille, France Lille University, Lille, France European Genomic Institute for Diabetes, Lille, France Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, U.K
| | - Jean-François Tanti
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| | - Mireille Cormont
- INSERM, UMR 1065, C3M, Team 7 Molecular and Cellular Physiopathology of Obesity and Diabetes, Nice, France Université Côte d'Azur, C3M, Nice, France
| |
Collapse
|
7
|
Hong YH, Betik AC, McConell GK. Role of nitric oxide in skeletal muscle glucose uptake during exercise. Exp Physiol 2014; 99:1569-73. [PMID: 25192731 DOI: 10.1113/expphysiol.2014.079202] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Nitric oxide is produced within skeletal muscle fibres and has various functions in skeletal muscle. There is evidence that NO may be essential for normal increases in skeletal muscle glucose uptake during contraction/exercise. Although there have been some discrepant results, it has been consistently demonstrated that inhibition of NO synthase (NOS) attenuates the increase in skeletal muscle glucose uptake during contraction in mouse and rat muscle ex vivo, during in situ contraction in rats and during exercise in humans. The NO-mediated increase in skeletal muscle glucose uptake during contraction/exercise is probably due to the modulation of intramuscular signalling that ultimately increases glucose transporter 4 (GLUT4) translocation and is, surprisingly, independent of blood flow. In this review, we discuss the evidence for and against a role of NO in regulating skeletal muscle glucose uptake during contraction/exercise and outline the possible mechanism(s) involved. Emerging findings regarding the role of neuronal NOS mu (nNOSμ) in this process are also discussed.
Collapse
Affiliation(s)
- Yet Hoi Hong
- College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne, Victoria, Australia Department of Physiology, Faculty of Medicine, University of Malaya, Malaysia
| | - Andrew C Betik
- College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne, Victoria, Australia
| | - Glenn K McConell
- College of Health and Biomedicine, Victoria University, Melbourne, Victoria, Australia Institute of Sport, Exercise and Active Living (ISEAL), Victoria University, Melbourne, Victoria, Australia
| |
Collapse
|
8
|
Gresele P, Migliacci R, Arosio E, Bonizzoni E, Minuz P, Violi F. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication. J Vasc Surg 2012; 56:1622-8, 1628.e1-5. [PMID: 22963812 DOI: 10.1016/j.jvs.2012.05.064] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2012] [Revised: 05/04/2012] [Accepted: 05/08/2012] [Indexed: 12/22/2022]
Abstract
BACKGROUND Peripheral arterial disease (PAD) is almost invariably associated with a generalized atherosclerotic involvement of the arterial tree and endothelial dysfunction. Previous short-term studies showed improvement of vascular reactivity and walking capacity in PAD patients by measures aimed at restoring nitric oxide (NO) production. NO is also known to prevent the progression of atherosclerosis. We wished to assess whether the prolonged administration of an NO-donating agent (NCX 4016) improves the functional capacity of PAD patients and affects the progression of atherosclerosis as assessed by carotid intima-media thickness (IMT). METHODS This prospective, double-blind, placebo-controlled study enrolled 442 patients with stable intermittent claudication who were randomized to NCX 4016 (800 mg, twice daily) or its placebo for 6 months. The primary study outcome was the absolute claudication distance on a constant treadmill test (10% incline, 3 km/h). The main secondary end point was the change of the mean far-wall right common carotid artery IMT. RESULTS The increase of absolute claudication distance at 6 months compared with baseline was 126±140 meters in the placebo-treated group and 117±137 meters in the NCX 4016-treated group, with no significant differences. Carotid IMT increased in the placebo-treated group (+0.01±0.01 mm; P=.55) and decreased in the NCX 4016-treated group (-0.03±0.01 mm; P=.0306). Other secondary end points did not differ between the two treatments. CONCLUSIONS Long-term NO donation does not improve the claudication distance but does reduce progression of atherosclerosis in patients with PAD. Further studies aimed at assessing whether long-term NO donation may prevent ischemic cardiovascular events are warranted.
Collapse
Affiliation(s)
- Paolo Gresele
- Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Perugia, Italy.
| | | | | | | | | | | |
Collapse
|
9
|
McConell GK, Rattigan S, Lee-Young RS, Wadley GD, Merry TL. Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. Am J Physiol Endocrinol Metab 2012; 303:E301-7. [PMID: 22550064 DOI: 10.1152/ajpendo.00667.2011] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Nitric oxide (NO) is an important vasodilator and regulator in the cardiovascular system, and this link was the subject of a Nobel prize in 1998. However, NO also plays many other regulatory roles, including thrombosis, immune function, neural activity, and gastrointestinal function. Low concentrations of NO are thought to have important signaling effects. In contrast, high concentrations of NO can interact with reactive oxygen species, causing damage to cells and cellular components. A less-recognized site of NO production is within skeletal muscle, where small increases are thought to have beneficial effects such as regulating glucose uptake and possibly blood flow, but higher levels of production are thought to lead to deleterious effects such as an association with insulin resistance. This review will discuss the role of NO in skeletal muscle during and following exercise, including in mitochondrial biogenesis, muscle efficiency, and blood flow with a particular focus on its potential role in regulating skeletal muscle glucose uptake during exercise.
Collapse
Affiliation(s)
- Glenn K McConell
- Institute of Sport, Exercise and Active Living and the School of Biomedical and Health Sciences, Victoria University, Footscray, Victoria, Australia.
| | | | | | | | | |
Collapse
|
10
|
Qian J, Fulton DJR. Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells. Front Physiol 2012; 3:3. [PMID: 22279436 PMCID: PMC3260459 DOI: 10.3389/fphys.2012.00003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Accepted: 01/04/2012] [Indexed: 01/10/2023] Open
Abstract
Nitric oxide (NO) has many beneficial actions on the vascular wall including suppression of inflammation. The mechanism(s) by which NO antagonizes cytokine signaling are poorly understood, but are thought to involve inhibition of the pro-inflammatory transcription factor, NF-κB. NO represses nuclear translocation of NF-κB via the S-nitrosylation of its subunits which decreases the expression of target genes including adhesion molecules. In previous studies, we have shown that the intracellular location of endothelial nitric oxide synthase (eNOS) can influence the amount of NO produced and that NO levels are paramount in regulating the S-nitrosylation of target proteins. The purpose of the current study was to investigate the significance of subcellular eNOS to NF-κB signaling induced by pro-inflammatory cytokines in human aortic endothelial cells (HAECs). We found that in HAECs stimulated with TNFα, L-NAME did not influence the expression of intercellular adhesion molecule 1 (ICAM-1) or vascular cell adhesion molecular 1 (VCAM-1). In eNOS "knock down" HAECs reconstituted with either plasma membrane or Golgi restricted forms of eNOS, there was no significant effect on the activation of the NF-κB pathway over different times and concentrations of TNFα. Similarly, the endogenous production of NO did not influence the phosphorylation of IκBα. In contrast, higher concentrations of NO derived from the use of the exogenous NO donor, DETA NONOate, effectively suppressed the expression of ICAM-1/VCAM-1 in response to TNFα and induced greater S-nitrosylation of IKKβ and p65. Collectively these results suggest that neither endogenous eNOS nor eNOS location is an important influence on inflammatory signaling via the NF-κB pathway and that higher NO concentrations are required to suppress NF-κB in HAECs.
Collapse
Affiliation(s)
- Jin Qian
- Vascular Biology Center, Georgia Health Sciences University Augusta, GA, USA
| | | |
Collapse
|
11
|
Tedong L, Madiraju P, Martineau LC, Vallerand D, Arnason JT, Desire DDP, Lavoie L, Kamtchouing P, Haddad PS. Hydro-ethanolic extract of cashew tree (Anacardium occidentale
) nut and its principal compound, anacardic acid, stimulate glucose uptake in C2C12 muscle cells. Mol Nutr Food Res 2010; 54:1753-62. [DOI: 10.1002/mnfr.201000045] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
12
|
Merry TL, Lynch GS, McConell GK. Downstream mechanisms of nitric oxide-mediated skeletal muscle glucose uptake during contraction. Am J Physiol Regul Integr Comp Physiol 2010; 299:R1656-65. [PMID: 20943856 DOI: 10.1152/ajpregu.00433.2010] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
There is evidence that nitric oxide (NO) is required for the normal increases in skeletal muscle glucose uptake during contraction, but the mechanisms involved have not been elucidated. We examined whether NO regulates glucose uptake during skeletal muscle contractions via cGMP-dependent or cGMP-independent pathways. Isolated extensor digitorum longus (EDL) muscles from mice were stimulated to contract ex vivo, and potential NO signaling pathways were blocked by the addition of inhibitors to the incubation medium. Contraction increased (P < 0.05) NO synthase (NOS) activity (∼40%) and dichlorofluorescein (DCF) fluorescence (a marker of oxidant levels; ∼95%), which was prevented with a NOS inhibitor N(G)-monomethyl-L-arginine (L-NMMA), and antioxidants [nonspecific antioxidant, N-acetylcysteine (NAC); thiol-reducing agent, DTT], respectively. L-NMMA and NAC both attenuated glucose uptake during contraction by ∼50% (P < 0.05), and their effects were not additive. Neither the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one, which prevents the formation of cGMP, the cGMP-dependent protein (PKG) inhibitor Rp-8-bromo-β-phenyl-1,N2-ethenoguanosine 3',5'-cyclic monophosphorothioate sodium salt nor white light, which breaks S-nitrosylated bonds, affects glucose uptake during contraction; however, DTT attenuated (P < 0.05) contraction-stimulated glucose uptake (by 70%). NOS inhibition and antioxidant treatment reduced contraction-stimulated increases in protein S-glutathionylation and tyrosine nitration (P < 0.05), without affecting AMPK or p38 MAPK phosphorylation. In conclusion, we provide evidence to suggest that NOS-derived oxidants regulate skeletal muscle glucose uptake during ex vivo contractions via a cGMP/PKG-, AMPK-, and p38 MAPK-independent pathway. In addition, it appears that NO and ROS may regulate skeletal muscle glucose uptake during contraction through a similar pathway.
Collapse
Affiliation(s)
- Troy L Merry
- Department of Physiology, University of Melbourne, Parkville, Victoria, Australia.
| | | | | |
Collapse
|
13
|
Gresele P, Marzotti S, Guglielmini G, Momi S, Giannini S, Minuz P, Lucidi P, Bolli GB. Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent. Diabetes Care 2010; 33:1262-8. [PMID: 20299485 PMCID: PMC2875435 DOI: 10.2337/dc09-2013] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Acute, short-term hyperglycemia enhances high shear stress-induced platelet activation in type 2 diabetes. Several observations suggest that platelets in type 2 diabetes are resistant to inhibition by aspirin. Our aim was to assess comparatively the effect of aspirin, a nitric oxide-donating agent (NCX 4016), their combination, or placebo on platelet activation induced by acute hyperglycemia in type 2 diabetes. RESEARCH DESIGN AND METHODS In a double-blind, placebo-controlled, randomized trial, 40 type 2 diabetic patients were allocated to 100 mg aspirin once daily, 800 mg NCX 4016 b.i.d., both of them, or placebo for 15 days. On day 15, 1 h after the morning dose, a 4-h hyperglycemic clamp (plasma glucose 13.9 mmol/l) was performed, and blood samples were collected before and immediately after it for platelet activation and cyclooxygenase-1 (COX-1) inhibition studies. RESULTS Acute hyperglycemia enhanced shear stress-induced platelet activation in placebo-treated patients (basal closure time 63 +/- 7.1 s, after hyperglycemia 49.5 +/- 1.4 s, -13.5 +/- 6.3 s, P < 0.048). Pretreatment with aspirin, despite full inhibition of platelet COX-1, did not prevent it (-12.7 +/- 6.9 s, NS vs. placebo). On the contrary, pretreatment with the NO donor NCX 4016, alone or in combination with aspirin, suppressed platelet activation induced by acute hyperglycemia (NCX 4016 +10.5 +/- 8.3 s; NCX 4016 plus aspirin: +12.0 +/- 10.7 s, P < 0.05 vs. placebo for both). Other parameters of shear stress-dependent platelet activation were also more inhibited by NCX 4016 than by aspirin, despite lesser inhibition of COX-1. CONCLUSIONS Acute hyperglycemia-induced enhancement of platelet activation is resistant to aspirin; a NO-donating agent suppresses it. Therapeutic approaches aiming at a wider platelet inhibitory action than that exerted by aspirin may prove useful in patients with type 2 diabetes.
Collapse
Affiliation(s)
- Paolo Gresele
- Section of Internal and Cardiovascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Zou XQ, Peng SM, Hu CP, Tan LF, Yuan Q, Deng HW, Li YJ. Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem 2010; 18:3020-5. [PMID: 20395149 DOI: 10.1016/j.bmc.2010.03.056] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2010] [Revised: 03/22/2010] [Accepted: 03/23/2010] [Indexed: 11/18/2022]
Abstract
Vascular complications are major causes of disability and death in patients with diabetes mellitus. It is often characterized by endothelial dysfunction. Studies have shown that either the loss of nitric oxide bioactivity or the decreased biosynthesis of NO is a central mechanism in endothelial dysfunction. As such, the delivery of exogenous NO is an attractive therapeutic option that has been used to slow the progress of diabetic vascular complications. In this paper, a novel group of hybrid nitric oxide-releasing chrysin derivatives was synthesized. The results indicated that all these chrysin derivatives exhibited in vitro inhibitory activities against aldose reductase and advanced glycation end-products formation. And some of them were even found to increase the glucose consumption of HepG2 cells. Furthermore, all compounds released NO upon incubation with phosphate buffer at pH 7.4. These hybrid ester NO donor prodrugs offer a potential drug design concept for the development of therapeutic or preventive agents for vascular complications due to diabetes.
Collapse
Affiliation(s)
- Xiao-Qing Zou
- Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410078, China
| | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Merry TL, McConell GK. Skeletal muscle glucose uptake during exercise: a focus on reactive oxygen species and nitric oxide signaling. IUBMB Life 2009; 61:479-84. [PMID: 19391163 DOI: 10.1002/iub.179] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Like insulin, muscle contraction (in vitro or in situ) and exercise increase glucose uptake into skeletal muscle. However, the contraction/exercise pathway of glucose uptake in skeletal muscle is an independent pathway to that of insulin. Indeed, skeletal muscle glucose uptake is normal during exercise in those who suffer from insulin resistance and diabetes. Thus, the pathway of contraction-mediated glucose uptake into skeletal muscle provides an attractive potential target for pharmaceutical treatment and prevention of such conditions, especially as skeletal muscle is the major site of impaired glucose disposal in insulin resistance. The mechanisms regulating skeletal muscle glucose uptake during contraction have not been fully elucidated. Potential regulators include Ca(2+) (via CaMK's and/or CaMKK), AMPK, ROS, and NO signaling, with some redundancy likely to be evident within the system. In this review, we attempt to briefly synthesize current evidence regarding the potential mechanisms involved in regulating skeletal muscle glucose uptake during contraction, focusing on ROS and NO signaling. While reading this review, it will become clear that this is an evolving field of research and that much more work is required to elucidate the mechanism(s) regulating skeletal muscle glucose uptake during contraction.
Collapse
Affiliation(s)
- Troy L Merry
- Department of Physiology, The University of Melbourne, Parkville, Victoria, Australia
| | | |
Collapse
|
17
|
|
18
|
Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A, Le Marchand-Brustel Y, Gual P, Tanti JF, Cormont M. Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 2009; 52:932-40. [PMID: 19219422 DOI: 10.1007/s00125-009-1273-3] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2008] [Accepted: 01/13/2009] [Indexed: 12/14/2022]
Abstract
AIMS/HYPOTHESIS Insulin resistance is caused by numerous factors including inflammation. It is characterised by defective insulin stimulation of adipocyte and muscle glucose transport, which requires the glucose transporter GLUT4 translocation towards the plasma membrane. Defects in insulin signalling can cause insulin resistance, but alterations in GLUT4 trafficking could also play a role. Our goal was to determine whether proteins controlling GLUT4 trafficking are altered in insulin resistance linked to obesity. METHODS Using real-time RT-PCR, we searched for selected transcripts that were differentially expressed in adipose tissue and muscle in obese mice and humans. Using various adipocyte culture models and in vivo mice treatment, we searched for the involvement of TNF-alpha in these alterations in obesity. RESULTS Sortilin mRNA and protein were downregulated in adipose tissue from obese db/db and ob/ob mice, and also in muscle. Importantly, sortilin mRNA was also decreased in morbidly obese human diabetic patients. Sortilin and TNF-alpha (also known as TNF) mRNA levels were inversely correlated in mice and human adipose tissues. TNF-alpha decreased sortilin mRNA and protein levels in cultured mouse and human adipocytes, an effect partly prevented by the peroxisome proliferator-activated receptor gamma activator rosiglitazone. TNF-alpha also inhibited adipocyte and muscle sortilin mRNA when injected to mice. CONCLUSIONS/INTERPRETATION Sortilin, an essential player in adipocyte and muscle glucose metabolism through the control of GLUT4 localisation, is downregulated in obesity and TNF-alpha is likely to be involved in this defect. Chronic low-grade inflammation in obesity could thus contribute to insulin resistance by modulating proteins that control GLUT4 trafficking.
Collapse
Affiliation(s)
- V Kaddai
- INSERM U895, Mediterranean Center of Molecular Medicine (C3M), Bâtiment Archimed, Nice Cedex 3, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Kaddai V, Gonzalez T, Keslair F, Grémeaux T, Bonnafous S, Gugenheim J, Tran A, Gual P, Le Marchand-Brustel Y, Cormont M. Rab4b is a small GTPase involved in the control of the glucose transporter GLUT4 localization in adipocyte. PLoS One 2009; 4:e5257. [PMID: 19590752 PMCID: PMC2707114 DOI: 10.1371/journal.pone.0005257] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2008] [Accepted: 03/13/2009] [Indexed: 12/31/2022] Open
Abstract
Background Endosomal small GTPases of the Rab family, among them Rab4a, play an essential role in the control of the glucose transporter GLUT4 trafficking, which is essential for insulin-mediated glucose uptake. We found that adipocytes also expressed Rab4b and we observed a consistent decrease in the expression of Rab4b mRNA in human and mice adipose tissue in obese diabetic states. These results led us to study this poorly characterized Rab member and its potential role in glucose transport. Methodology/Principal Findings We used 3T3-L1 adipocytes to study by imaging approaches the localization of Rab4b and to determine the consequence of its down regulation on glucose uptake and endogenous GLUT4 location. We found that Rab4b was localized in endosomal structures in preadipocytes whereas in adipocytes it was localized in GLUT4 and in VAMP2-positive compartments, and also in endosomal compartments containing the transferrin receptor (TfR). When Rab4b expression was decreased with specific siRNAs by two fold, an extent similar to its decrease in obese diabetic subjects, we observed a small increase (25%) in basal deoxyglucose uptake and a more sustained increase (40%) in presence of submaximal and maximal insulin concentrations. This increase occurred without any change in GLUT4 and GLUT1 expression levels and in the insulin signaling pathways. Concomitantly, GLUT4 but not TfR amounts were increased at the plasma membrane of basal and insulin-stimulated adipocytes. GLUT4 seemed to be targeted towards its non-endosomal sequestration compartment. Conclusion/Significance Taken our results together, we conclude that Rab4b is a new important player in the control of GLUT4 trafficking in adipocytes and speculate that difference in its expression in obese diabetic states could act as a compensatory effect to minimize the glucose transport defect in their adipocytes.
Collapse
Affiliation(s)
- Vincent Kaddai
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
| | - Teresa Gonzalez
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
| | - Frédérique Keslair
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
| | - Thierry Grémeaux
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
| | - Stéphanie Bonnafous
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 8, Hepatic Complications in Obesity, Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- CHU of Nice, Pôle Digestif, Hôpital Archet 2, Nice, France
| | - Jean Gugenheim
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 8, Hepatic Complications in Obesity, Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- CHU of Nice, Pôle Digestif, Hôpital Archet 2, Nice, France
| | - Albert Tran
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 8, Hepatic Complications in Obesity, Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- CHU of Nice, Pôle Digestif, Hôpital Archet 2, Nice, France
| | - Philippe Gual
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 8, Hepatic Complications in Obesity, Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- CHU of Nice, Pôle Digestif, Hôpital Archet 2, Nice, France
| | - Yannick Le Marchand-Brustel
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 8, Hepatic Complications in Obesity, Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- CHU of Nice, Pôle Digestif, Hôpital Archet 2, Nice, France
| | - Mireille Cormont
- INSERM U895, Centre Méditerranéen de Médecine Moléculaire (C3M), Team 7, Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France
- Faculty of Medicine, University of Nice/Sophia-Antipolis, Nice, France
- * E-mail:
| |
Collapse
|